MC

500.5

-0.66%↓

SANES

9.558

-0.95%↓

SAF

317.6

+1.02%↑

BBVA

18.375

-0.62%↓

BNP

86.24

-0.67%↓

MC

500.5

-0.66%↓

SANES

9.558

-0.95%↓

SAF

317.6

+1.02%↑

BBVA

18.375

-0.62%↓

BNP

86.24

-0.67%↓

MC

500.5

-0.66%↓

SANES

9.558

-0.95%↓

SAF

317.6

+1.02%↑

BBVA

18.375

-0.62%↓

BNP

86.24

-0.67%↓

MC

500.5

-0.66%↓

SANES

9.558

-0.95%↓

SAF

317.6

+1.02%↑

BBVA

18.375

-0.62%↓

BNP

86.24

-0.67%↓

MC

500.5

-0.66%↓

SANES

9.558

-0.95%↓

SAF

317.6

+1.02%↑

BBVA

18.375

-0.62%↓

BNP

86.24

-0.67%↓

Search

Bayer AG

Closed

SectorFinance

36.29 -3.64

Overview

Share price change

24h

Current

Min

36.21

Max

36.475

Key metrics

By Trading Economics

Income

-769M

-959M

Sales

-1.1B

9.7B

Dividend yield

0.26

Profit margin

-9.928

Employees

88,502

EBITDA

370M

606M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+17.09% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.26%

4.37%

Next Earnings

12 maj 2026

Market Stats

By TradingEconomics

Market Cap

13B

40B

Previous open

39.93

Previous close

36.29

News Sentiment

By Acuity

28%

72%

63 / 442 Ranking in Finance

Technical Score

By Trading Central

Confidence

Bearish Evidence

Bayer AG Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 mar 2026, 11:06 UTC

Earnings

Bayer Net Loss Widens on Weedkiller Litigation Charges -- 2nd Update

4 mar 2026, 07:45 UTC

Earnings

Bayer Net Loss Widens on Weedkiller Litigation Charges -- Update

4 mar 2026, 07:09 UTC

Earnings

Bayer Net Loss Widens on Weedkiller Litigation Charges

3 mar 2026, 15:20 UTC

Major Market Movers
Major News Events

European Stocks on Track for Worst Session Since 'Liberation Day' Selloff

5 mar 2026, 07:03 UTC

Market Talk

Bayer's Roundup Settlement Isn't a Done Deal Yet -- Market Talk

4 mar 2026, 12:52 UTC

Market Talk
Earnings

Bayer Sees Pharma Business Turning a Corner -- Market Talk

4 mar 2026, 12:41 UTC

Market Talk

Bayer Expects Consumer Sales to Remain Under Pressure in U.S., China -- Market Talk

4 mar 2026, 12:13 UTC

Market Talk

Bayer Expects Challenging Agriculture Market in 2026 -- Market Talk

4 mar 2026, 10:18 UTC

Hot Stocks

Stocks to Watch Wednesday: CrowdStrike, Gitlab, Moderna, Strategy, Coinbase -- WSJ

4 mar 2026, 08:32 UTC

Market Talk
Earnings

Bayer Beats Expectations, But Currency Headwinds Cloud Outlook -- Market Talk

4 mar 2026, 06:41 UTC

Earnings

Bayer: Paul Achleitner and Colleen Goggins Won't Stand for Re-election at 2026 AGM

4 mar 2026, 06:41 UTC

Earnings

Bayer Proposes Marcel Smits and Alfred Stern as Supervisory Board Members

4 mar 2026, 06:40 UTC

Earnings

Bayer Proposes Two New Candidates for Supervisory Board

4 mar 2026, 06:40 UTC

Earnings

Bayer: 2026-End Net Debt Expected at EUR32B to EUR33B

4 mar 2026, 06:39 UTC

Earnings

Bayer Sees 2026 Free Cash Outflow of EUR1.5B-EUR2.5B Due to Litigation Payouts

4 mar 2026, 06:39 UTC

Earnings

Bayer: 2025 Core EPS Would Have Been EUR4.57 Under New Methodology

4 mar 2026, 06:38 UTC

Earnings

Bayer: Changing the Way it Calculates Core EPS

4 mar 2026, 06:38 UTC

Earnings

Bayer Sees 2026 Core EPS at EUR4.30-EUR4.80

4 mar 2026, 06:37 UTC

Earnings

Bayer Sees 2026 Ebitda Before Special Items of EUR9.6B to EUR10.1B

4 mar 2026, 06:37 UTC

Earnings

Bayer Sees 2026 Sales of EUR45B to EUR47B Adjusted for Currency Changes

4 mar 2026, 06:35 UTC

Earnings

Bayer 4Q Adj EPS EUR0.62

4 mar 2026, 06:34 UTC

Earnings

Bayer: Results, Outlook Reflect U.S. Settlement to Resolve Current, Future Roundup Claims

4 mar 2026, 06:33 UTC

Earnings

Bayer Declares Dividend of EUR0.11 a Share

4 mar 2026, 06:32 UTC

Earnings

Bayer Sees Stable 2026 Sales, Earnings Adjusted for Currency Changes

4 mar 2026, 06:32 UTC

Earnings

Analysts Saw Bayer 4Q Ebitda Before Special Items at EUR1.92B

4 mar 2026, 06:31 UTC

Earnings

Analysts Saw Bayer 4Q Sales at EUR11.31B

4 mar 2026, 06:31 UTC

Earnings

Bayer 4Q EBIT Loss EUR2.87B

4 mar 2026, 06:31 UTC

Earnings

Bayer 4Q Net Loss EUR3.76B

4 mar 2026, 06:30 UTC

Earnings

Bayer 4Q Ebitda Before Special Items EUR1.97B

4 mar 2026, 06:30 UTC

Earnings

Bayer 4Q Sales EUR11.44B

Peer Comparison

Price change

Bayer AG Forecast

Price Target

By TipRanks

17.09% upside

12 Months Forecast

Average 42.61 EUR  17.09%

High 54.5 EUR

Low 23 EUR

Based on 10 Wall Street analysts offering 12 month price targets forBayer AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

10 ratings

5

Buy

4

Hold

1

Sell

Technical Score

By Trading Central

22.99 / 23.88Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

63 / 442 Ranking in Finance

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.
help-icon Live chat